ICL and TICL counter LASIK slowdown

Article

David Bailey, president of international operations at Staar Surgical, makers of the Visian ICL & TICL, says ICL technology allows surgeons to differentiate themselves in the slowing LASIK marketplace. Mr Bailey was speaking at a media briefing during this year's congress of the ESCRS in Berlin, Germany.

David Bailey, president of international operations at Staar Surgical, makers of the Visian ICL & TICL, says ICL technology allows surgeons to differentiate themselves in the slowing LASIK marketplace. Mr Bailey was speaking at a media briefing during this year’s congress of the ESCRS in Berlin, Germany.

“Differentiation is critically important in a down market. LASIK is well down, the price is down. Doctors and practices are asking themselves how they can compete to get a bigger piece of a smaller pie. As a company, our goal is to provide doctors with the technology that allows them to differentiate themselves.”

Bailey says LASIK surgeons should be providing ICL and Toric ICL implantation as a complimentary procedure to LASIK. Mark Rosenberg, CEO of the Barnet Dulaney Perkins eye centre in Phoenix, Arizona, US, agrees that doctors need to think about refractive procedures, not LASIK versus ICL or TICL.

Rosenberg has seen strong growth in the lens-based sector. But, before this can be achieved, he says practices need to work to overcome the barriers to ICL uptake amongst patients. He says clinics must present ICLs at the beginning of the consultation process, rather than only where LASIK is not an option. They must also streamline scheduling for the convenience of the patient and talk about quality of vision rather than price.

Rosenberg says doctors need to shift the way they think, embracing the broader concept of vision correction rather than only LASIK. “The only question for surgeons is, are you going to be left off the train and wind up giving up on refractive surgery, or are you going to move on?”

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.